Predicting the risk of developing diabetes in steatotic liver disease using controlled attenuation parameter in a health checkup population

作者：T. Nakatsuka, Y. Yamaji, Ryosuke Tateishi, Takako Ogasawara, Rena Mihara, Yoshiaki Kawashima, Tetsuharu Ono, Tomoharu Yamada, Tatsuya Minami, Masaya Sato, Takeshi Hayashi, Yuki Matsushita, Kazuyoshi Funato, Tatsuya Sato, Tomotaka Saito, Yotaro Kudo, Kogure Hirofumi, Hayato Nakagawa, Yoshinari Asaoka, Yasuo Tanaka, Yousuke Nakai, Hideaki Ijichi, Mitsuhiro Fujishiro · 发表于：Hepatology Research · 年份：2025 · DOI：10.1111/hepr.14216 · 被引用次数：2 · 研究领域：Liver Disease Diagnosis and Treatment、Diabetes, Cardiovascular Risks, and Lipoproteins、Nutrition and Health in Aging

Abstract Introduction Excessive hepatic steatosis is linked to systemic metabolic disorders. We investigated the association between hepatic steatosis quantified by controlled attenuation parameter (CAP) and the development of type 2 diabetes mellitus (T2DM) in a health checkup population. Methods The present retrospective cohort study included 1636 participants without T2DM who underwent CAP measurement and were followed up at annual health checkups. Cox proportional hazards regression was used to identify risk factors for T2DM development. Results During a mean follow‐up of 3.2 years, 181 participants developed T2DM. The cumulative incidence rates of T2DM were significantly higher in participants with severe steatosis (CAP ≥ 280 dB/m) compared with those without (13.9% vs. 4.8% at 3 years, p < 0.001). Multivariate analysis identified CAP as an independent predictor of new‐onset T2DM (adjusted hazard ratio [aHR], 1.04 per 10 dB/m increase; 95% confidence interval [CI], 1.01–1.08, p = 0.01), along with fasting plasma glucose (aHR, 2.13 per 10 mg/dL; 95% CI, 1.77–2.55, p < 0.001), HbA1c (aHR, 1.25 per 0.1% increase; 95% CI, 1.19–1.32, p < 0.001), and platelet count (aHR, 0.95 per 10 4 /μL increase; 95% CI, 0.92–0.98, p = 0.001). A dose–response relationship was observed between CAP level and T2DM risk. In addition, suspected compensated advanced chronic liver disease (liver stiffness ≥10 kPa) and at‐risk steatohepatitis (FibroScan‐AST score ≥0.67) were associated with...